Using a similar polyclonal antibody, cytoplasmic Survivin expression has been described in 93% of malignant melanomas (Grossman et al, 1999a), 81% of basal cell carcinomas, 92% of cutaneous squamous cell carcinomas (Grossman et al, 1999b), 88% of gastric carcinomas (Okada et al, 2001) and 100% of oesophageal cancers (Beardsmore et al, 2001). Here, BIRC5 is linked to cutaneous squamous cell carcinoma.